Exhibit 107.1
CALCULATION OF FILING FEE TABLES
FORM S-3
(Form Type)
SOLENO THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security Type | Security Class Title | Fee Calculation Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||||
Fees to be Paid | Equity | Common stock, par value $0.001 per share | 457(o) | (1) | (1) | (1) | — | — | ||||||||
Fees to be Paid | Equity | Pre-funded warrants to purchase common stock | 457(o) | (1) | (1) | (1) | — | — | ||||||||
Fees to be Paid | Unallocated Shelf | Unallocated Shelf | 457(o) | (1) | (1) | $11,865,452.60 (1) | $110.20 per $1,000,000 | $1,307.57 | ||||||||
Total Offering Amounts | $11,865,452.60 (1) | $1,307.57 | ||||||||||||||
Total Fees Previously Paid | — | |||||||||||||||
Total Fee Offsets | — | |||||||||||||||
Net Fee Due | $1,307.57 |
(1) | The registrant previously registered the offer and sale of certain securities, including its common stock, par value $0.001 per share and warrants to purchase common stock, having a proposed maximum aggregate offering price of $100,000,000 pursuant to a Registration Statement on Form S-3 (File No. 333-252108) (the “Prior Registration Statement”), which was initially filed on January 14, 2021 and declared effective by the Securities and Exchange Commission on February 9, 2021. As of the date hereof, a balance of $59,327,263.10 of such securities remains unsold under the Prior Registration Statement. In accordance with Rule 462(b) under the Securities Act of 1933, as amended, and General Instruction IV(A) of Form S-3, the registrant is hereby registering the offer and sale of an additional $11,865,452.60 of its shares of common stock. The additional amount of securities that is being registered for offer and sale represents no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Prior Registration Statement. |